<DOC>
	<DOCNO>NCT03037151</DOCNO>
	<brief_summary>This study evaluate safety efficacy combination treatment grazoprevir + elbasvir compensate cirrhotic participant chronic genotype 1 ( GT1 ) genotype 6 ( GT6 ) hepatitis C virus ( HCV ) infection without human immunodeficiency virus ( HIV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Grazoprevir Elbasvir GT1ang GT6 With Without HIV</brief_title>
	<detailed_description>Total 100 patient compensated cirrhosis , chronically infect HCV GT1 GT6 without HIV infection include . Patients HCV GT1 GT6 enrol 1:1 basis ( approximately 50 patient GT1 50 patient GT6 ) . Treatment-naïve patient treat combination grazoprevir plus elbasvir 12 week . Treatment-experienced patient , include null responder , partial responder post-treatment relapsers , assign treat combination plus weight-based RBV 16 week . The dosage study drug 100 mg grazoprevir daily 50 mg elbasvir daily . All patient follow assess SVR ( define HCV RNA level &lt; 12 IU/mL ) week12 week 24 treatment ( SVR12 SVR24 , respectively ) . Additionally , participant evaluate longitudinal change LS value TE 240 week ( 5 year ) treatment</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1 . Men woman age 18 year old 2 . Documented chronic HCV GT1 GT6 ( positive antiHCV antibody HCV RNA least 6 month prior screen ) 3 . HCV RNA least 10,000 IU/ml 4 . Cirrhosis define : liver biopsy show cirrhosis METAVIR F4 ; TE show cirrhosis result &gt; 13.0 kPa 5 . Treatmentnaïve individual chronic HCV infection 6 . Treatmentexperienced individual ( Previous treatment failure PEGIFN plus RBV ) chronic HCV infection 7 . HIVinfected participant enrol study must meet following criterion : 7.1 Documented HIV infection 7.2 Naïve treatment antiretroviral therapy ( ART ) HIV ART least 8 week prior study entry use dual nucleoside reverse transcriptase inhibitor ( NRTI ) backbone tenofovir abacavir either emtricitabine lamivudine plus raltegravir ( dolutegravir rilpivirine ) 7.3 CD4+ Tcell count &gt; 200 cells/mm3 ART &gt; 500 cell/mm3 ART treatment naïve 7.4 Undetectable plasma HIVRNA least 8 week prior screen ART &lt; 50,000 copies/mL ART treatment naïve 8 . Agree use two acceptable method birth control least 2 week prior Day 1 continue least 6 month last dose study drug , longer dictate local regulation ( female subject childbearing potential male subject female sexual partner childbearing potential ) . 1 . Evidence decompensated liver disease ( ChildPugh Class B C ChildPugh score &gt; 6 , platelet le 75 × 10³/μL , serum albumin &lt; 3·0 g/dL , presence history ascites , gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease ) 2 . Coinfected hepatitis B virus 3 . Has cirrhosis liver image within 6 month show evidence HCC evaluation HCC 4 . Pregnant breastfeed day 1 anytime treatment , 14 day last dose study medication 5 . Any medical condition require likely require chronic systemic administration corticosteroid immunosuppressant drug course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>grazoprevir</keyword>
	<keyword>elbasvir</keyword>
	<keyword>compensate cirrhosis</keyword>
	<keyword>genotype 1 ( GT1 )</keyword>
	<keyword>genotype 6 ( GT6 )</keyword>
	<keyword>hepatitis virus C ( HCV )</keyword>
	<keyword>human immunodeficiency virus ( HIV )</keyword>
</DOC>